CD83 and myeloid sarcoma: NMOSD patients exhibited a lower sCD83/CD83 expression ratio compared to HCs (0.71 ± 0.16 vs 1.04 ± 0.48, p = 0.02, Figure 1b), MOGAD patients (0.71 ± 0.16 vs 1.02 ± 0.39, p = 0.04, Figure 1b), and MS patients (0.71 ± 0.16 vs 1.16 ± 0.45, p=0.006, Figure 1b).